

New Scientific Publication Highlights Benefits of NTI164 for Neuroinflammation and Neuronal Protection

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces the publication of new NTI164 pre-clinical data in the peer-reviewed Journal *Biomolecules*.

The publication is titled "Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity" and led by Dr Bobbi Fleiss, School of Health & Biomedical Sciences, RMIT University, Victoria, Australia.

The pre-clinical research describes the immunomodulatory and neuroprotective effects of NTI164, Neurotech broad spectrum cannabinoid drug therapy. Previous studies have focused primarily on the therapeutic potential of the major components of cannabis plant extract as isolates or combined. However, the researchers have explored the pharmacological benefits of NTI164, which is very low in THC, and therefore an ideal candidate for paediatric populations and has formed the basis of Neurotech's multiple clinical trials all having reported statistically significant and clinically meaningful improvements without compromising safety.

Overall, the scientific research shows that the anti-inflammatory and neuroprotective effects of NTI164 as a full-spectrum cannabis extract are enhanced relative to that of Cannabidiol (CBD) alone. Inflammation-induced up regulation of microglial inflammatory markers was significantly attenuated by NTI164, but not by CBD. NTI164 promoted undifferentiated neuron proliferation and differentiated neuron survival under excitotoxic conditions.

The findings suggest that the anti-inflammatory and neuroprotective effect of NTI164 is likely due to the synergistic interaction of the highly purified and reproducibly manufactured cannabinoids comprising NTI164 rather than isolated CBD supporting the entourage effect of NTI164.

The data highlights the potential therapeutic efficacy of NTI164 for disorders associated with persistent or progressive neuroinflammation. To date, Neurotech has reported positive clinical trial data for Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) (collectively PANDAS/PANS) and Rett Syndrome.

A copy of the publication is available at: <u>https://www.mdpi.com/2218-273X/14/11/1434</u>

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy Executive Director td@neurotechinternational.com +61 (0)402 493 727

Neurotech International Ltd Suite 5 CPC, 145 Stirling Highway Nedlands, Western Australia 6009 T: +61 (8) 9389 3130
E: info@neurotechinternational.com
W: neurotechinternational.com

ABN: 73 610 205 402 ASX: NTI



Neurotech International Limited (ASX:NTI)) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <u>http://www.neurotechinternational.com</u>.

About NTI164

NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (M<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

T: +61 (8) 9389 3130 E: info@neurotechinternational.com W: neurotechinternational.com ABN: 73 610 205 402 ASX: NTI